Relay Therapeutics, Inc. announced the appointments of Tara O’Meara as senior vice president of clinical development operations, and Charles Ferté, M.D., Ph.D., as vice president, global medical lead for RLY-4008. Ms. O’Meara and Dr. Ferté bring decades of experience in the strategic oversight and execution of multiple drug development programs and will further strengthen the clinical team and Relay Therapeutics’ ability to bring lifesaving therapies to patients. Ms. O’Meara spent nearly a decade at bluebird bio, initially overseeing the development and execution of the clinical program for a rare genetic disease, and most recently, leading the clinical development operations department where she had strategic oversight across all development programs, including severe genetic disease and oncology. Prior to bluebird bio, Ms. O’Meara directed the clinical operations group for Synageva BioPharma, now Alexion Pharmaceuticals, and held multiple roles at the Genzyme Corporation, now Sanofi Genzyme, including global team leader for a clinical development program in Pompe disease. Dr. Ferté has over 15 years of R&D experience in oncology drug development, both in academia and industry. Having held multiple roles at AstraZeneca, Dr. Ferté most recently served as senior director and global project leader in AstraZeneca’s oncology R&D division where he oversaw the development of multiple immune-oncology assets. Before AstraZeneca, Dr. Ferté was a physician scientist at the Institute Gustave Roussy (IGR) in Paris, France, working as a senior attending medical oncologist in the Early Drug Development (DITEP), GI and Head and Neck units. Dr. Ferté has served as co-chair of the iRECIST group, part of the official RECIST working group, since 2019, and has co-authored 60+ patents and publications in peer-reviewed journals across multiple oncology disease areas.
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Companyâs Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Companyâs lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
RELAY THERAPEUTICS, INC. 
